XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 3 Months Ended
Dec. 18, 2020
shares
Sep. 14, 2020
Mar. 31, 2021
USD ($)
Segment
$ / shares
shares
Mar. 31, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
Summary Of Significant Accounting Policies [Line Items]            
Net loss | $     $ (8,499,000) $ (8,177,000)    
Cash and cash equivalents | $     108,579,000 $ 11,785,000 $ 114,195,000 $ 8,791,000
Working capital | $     106,000,000      
Accumulated deficit | $     $ (88,892,000)   (80,393,000)  
Cash, cash equivalents and restricted cash, maturity period     three months or less      
Cash equivalents | $     $ 9,200,000   $ 9,200,000  
Number of operating business segments | Segment     1      
Warrants exercise price | $ / shares     $ 0.001      
Antidilutive securities excluded from computation of earnings per share, amount     4,659,416 528,659    
2014 Stock Incentive Plan [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Increase in number of shares of common stock authorized for issuance       28,816    
Common stock, number of shares reserved for issuance         0  
ESPP [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Increase in number of shares of common stock authorized for issuance       7,204    
Common stock, number of shares reserved for issuance     24,077      
2020 Plan [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Common stock, number of shares reserved for issuance 4,860,000   4,135,044      
Percentage of issued and outstanding shares of common stock 15.00%          
Equity compensation period 3 years          
Stock Options [Member] | Board of Directors [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Expected life assumption using simplified method, description     For stock options granted to the board of directors, the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account for the extended range of time of 12 to 18 months vested stock options granted to board of directors may be exercised upon termination.      
Expected life assumption using simplified method     12 months      
Stock Options [Member] | Minimum [Member] | Board of Directors [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Vesting period of stock options granted     12 months      
Stock Options [Member] | Maximum [Member] | Board of Directors [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Vesting period of stock options granted     18 months      
Warrants [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Basic weighted average shares outstanding     509,117      
Anelixis [Member] | Minimum [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Expected life assumption using simplified method   5 years        
Anelixis [Member] | Maximum [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Expected life assumption using simplified method   5 years 10 months 24 days        
Otic Pharma [Member] | Anelixis [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Ownership percentage     100.00%      
Otic Pharma, Inc. [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Ownership percentage     100.00%